Prospective Non-interventional Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment
Condition: Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Study Type: Observational
Clinical Trials Identifier NCT 8-digits: NCT03647878
Sponsor: Ipsen
Phase:
Eligibility:
- Age: minimum 18 Years maximum N/A
- Gender: All
Inclusion Criteria:
- Males or females aged 18 years and older with capacity to consent.
- Subjects receiving cabozantinib as monotherapy or in combination with nivolumab as a first line treatment for advanced or metastatic renal cell carcinoma
- Subjects with the intention to be treated with cabozantinib tablets as monotherapy or in combination with nivolumab according to the current local Summary of Product Characteristics (SmPC); decision has to be taken before entry in the study.
- Signed written informed consent
Exclusion Criteria:
- Participation in an interventional study at the same time and/or within 3 months before baseline.
- Previous participation in this study
View trial on ClinicalTrials.gov